Elacestrant(Orserdu)

Another NameOrserdu、依拉司群、RAD1901、埃拉司群、艾拉司群

IndicationsIndicated for ER-positive, HER2-negative, ESR1-mutant advanced/metastatic breast cancer in postmenopausal women or adult men with disease progression after at least one line of endocrine therapy.